Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Other Non-Current Liabilities data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 69.57% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 69.57% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 65.22% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $3.5 million, down from $4.0 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for PHAT reached as high as $11.5 million in Q4 2024 and fell as low as $3.5 million in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $8.6 million across 5 years, with a median of $7.5 million in 2022.
• Across the five-year window, Other Non-Current Liabilities jumped 81.82% in 2022 and tumbled 69.57% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $7.5 million in 2022, then increased by 29.33% to $9.7 million in 2023, then climbed by 18.56% to $11.5 million in 2024, then sank by 65.22% to $4.0 million in 2025, then slipped by 12.5% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $3.5 million in Q1 2026, $4.0 million in Q4 2025, and $11.5 million in Q3 2025.